Transcriptional profiles of circulating tumor cells reflect heterogeneity and treatment resistance in advanced prostate cancer
Molecular subtypes of mPC can be distinguished by transcriptional profiling of CTCs. In the future, our convenient PCR-based analysis may complement the monitoring of advanced PCa patients and allow timely detection of resistance to androgen receptor pathway inhibitors.
Authors
- Lina Bergmann (ORCID: https://orcid.org/0000-0003-1916-1632)
- Nadja Strewinsky
- Tina Rohlfing
- Gunhild von Amsberg (ORCID: https://orcid.org/0000-0002-5176-0507)
- Klaus Pantel (ORCID: https://orcid.org/0000-0001-5736-2772)
- Simon A. Joosse (ORCID: https://orcid.org/0000-0002-4296-5615)
- Sarah Greimeier (ORCID: https://orcid.org/0000-0002-2495-7910)
- Tobias Busenbender
- Sabine Riethdorf (ORCID: https://orcid.org/0000-0003-0028-5643)
- Sergey A. Dyshlovoy (ORCID: https://orcid.org/0000-0002-7155-9245)
- Moritz Kaune
- Stefan Werner (ORCID: https://orcid.org/0000-0002-2451-9371)
- Sven Peine (ORCID: https://orcid.org/0000-0002-6365-9916)
Institutions
- Universität Hamburg (DE)
- University Medical Center Hamburg-Eppendorf (DE)
- Martini-Klinik (DE)
- University Cancer Center Hamburg (DE)
Publication Details
- Journal
- Journal of Experimental & Clinical Cancer Research
- Published
- 2025-04-03
- DOI
- https://doi.org/10.1186/s13046-025-03367-x
- Citations
- 7
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 10.63